Top news of the week: 09.01.2023.
FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
Eisai's newly approved Alzheimer's drug, Leqembi, has limitations but is groundbreaking in a field that hasn’t seen real medical progress in decades.
A Valuable COVID Drug Doesn’t Work against New Variants
Current monoclonal antibodies fail against COVID virus variants, so drugmakers want to use a fast-track test for new ones
New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease
Eisai and Biogen’s Leqembi is the first drug to show that reducing a protein linked to Alzheimer’s helped patients.
Professional development
London United Kingdom 18/04/2023 Regulation of In-Vitro Diagnostics Medical Devices Module 19 of the MSc and Masterclass: Primarily focusing on the In Vitro Diagnostic Regulation, …
Trendspotting: Hybrid and Decentralized Clinical Trials, Patient-Centricity, and Increased Remote Patient Monitoring in 2023
In addition, cell and gene therapies will become digitized and contribute to the drive for more precise personalized medicine.” Here are the full trends and predictions, including …